
Kawasaki disease (KD) is an acute onset, childhood systemic vasculitis with the most important complication being coronary artery injury with aneurysm formation. In the pathogenesis of KD, innate immune overactivation is well recognized, but the role of adaptive immunity in the progression of vascular lesions is not completely understood. A local lesion in the coronary artery is thought to connect to the systemic inflammatory reaction through CD8+ T cells. In this review, we discuss evidence from peripheral blood immunophenotyping, single cell transcriptomics, TCR clonal repertoire profiling, human coronary artery pathology and KD like animal models to delineate CD8⁺ T-cell signatures and their proposed pathogenic mechanisms. The circulating CD8+ T cells from acute-phase patients have decreased numbers, increased activation markers, skewed subset distribution, and co-existent proliferative and CTL and exhaustion phenotype transcription profiles in conjunction with TCR clonal expansion. CD8+ T cells appear to infiltrate the coronary arterial lesions in human autopsy samples and CD8+ T cells induce coronary arteritis in murine models. Interestingly, classical perforin-granzyme-mediated cytotoxicity of lesional CD8+ T cells is not confirmed in human KD, underscoring a crucial gap between peripheral omics signatures, data in animal models and evidence in human tissues. The in situ effector mechanisms of disease driving CD8+ T cells subsets, and their feasibility as clinical biomarkers, warrant further investigation and may lead to precision risk stratification and targeted immunotherapies in KD related vascular complications, using multicenter prospective cohorts and paired blood and tissue functional assays.
Low-dose interleukin-2 (LD-IL-2) is being developed as an immune-regulatory therapy across rheumatic and autoimmune diseases, but its biology cannot be reduced to regulatory T-cell (Treg) expansion. IL-2 responses are determined by dose and exposure, receptor abundance and binding kinetics, activation state, tissue distribution, and the balance among JAK-STAT5, PI3K-AKT-mTOR, and RAS-MAPK signaling. CD25-high Tregs have a competitive advantage at low concentrations, yet activated conventional T cells, CD8 + T cells, natural killer cells, follicular T-cell subsets, B-cell compartments, and tissue-resident populations may also be modulated directly or indirectly. We therefore synthesize the field through a cross-disease framework linking receptor pharmacology, signaling thresholds, Treg heterogeneity, epigenetic and metabolic fitness, receptor trafficking, and tissue microenvironments to pharmacodynamic, clinical, and durable responses. Disease-specific evidence is critically compared rather than interpreted as a uniform IL-2-deficiency syndrome: systemic lupus erythematosus combines T-cell IL-2 deficiency with Tfh-B-cell and age-associated B-cell pathology; inflammatory arthritis is constrained by synovial cytokine consumption and tissue access; systemic sclerosis by vascular-fibrotic remodeling; inflammatory myopathy by muscle, skin, lung, and microbiome contexts; and neurological autoimmunity by blood–brain-barrier penetration and compartmentalized inflammation. Randomized evidence supports biological activity and preliminary efficacy in selected settings, whereas many indications remain supported by small, uncontrolled studies. Native LD-IL-2 and engineered agonists also require separate evaluation because altered affinity and half-life can change cellular selectivity, immunogenicity, biodistribution, and the risk of chronic receptor overstimulation. We conclude that development should prioritize disease-specific dose-exposure relationships, functional and tissue-resolved biomarkers, rigorous clinical endpoints, and long-term surveillance. This framework positions IL-2 therapy as context-dependent network modulation rather than universal restoration of immune tolerance.
Pollen-food allergy syndrome (PFAS) is commonly associated with localized oral symptoms, yet mugwort-related reactions can include anaphylaxis. Evidence on these severe presentations is dispersed across heterogeneous studies, complicating clinical recognition and risk assessment. This review synthesizes current evidence on the clinical spectrum, molecular pathways, diagnosis and management of mugwort-related PFAS associated with anaphylaxis. The literature identifies geographically overlapping molecular pathways. The Art v 3/non-specific lipid transfer protein (nsLTP) pathway is prominent in northern Chinese cohorts, whereas the Art v 1/Api g 7 defensin pathway is well characterized in European celery-allergic populations. nsLTP-mediated food allergy is also important in Mediterranean populations, where Art v 3 co-sensitization does not establish primary mugwort sensitization. Profilin-mediated reactions, including those associated with Art v 4, are generally localized; emerging allergens such as fructose-bisphosphate aldolase require further investigation. Some implicated food allergens retain IgE-binding activity after heating or digestion, which may contribute to reactions to cooked or processed foods. Evidence is largely derived from referral cohorts, case reports and molecular studies, with heterogeneous definitions and ascertainment of anaphylaxis. Population prevalence and individual risk remain uncertain. Component testing can guide investigation of plausible pathways but cannot independently establish clinical food allergy or predict anaphylaxis. Clinical history, relevant food exposures and cofactors should guide targeted testing, dietary advice and emergency preparedness. Prospective studies with harmonized definitions and clinically confirmed outcomes are needed to validate proposed phenotypes and risk-assessment approaches.
Complement activation–related pseudoallergy (CARPA) describes a proposed non-IgE-mediated hypersensitivity mechanism in which complement activation contributes causally, often through generation of the anaphylatoxins C3a and C5a. These mediators may activate responsive effector cells and contribute to systemic inflammatory responses that clinically resemble anaphylaxis. Complement activation and complement-associated immediate reactions have been reported with several therapeutic agents and drug-delivery systems, including micelle-solubilized formulations, liposomal drugs, nanoparticle-based therapeutics, PEGylated agents, and biologic therapies; however, the strength of causal evidence varies among products. Importantly, reactions may be driven not only by the active pharmaceutical ingredient but also by formulation components, such as surfactants, solubilizing agents, lipid carriers, and other drug vehicles. As compounded injectable therapies, including intralesional dutasteride, become increasingly used in dermatology, clinicians should recognize that formulation vehicles vary among manufacturers and compounding pharmacies. Certain formulations may contain complement-activating excipients, such as Cremophor EL (polyoxyethylated castor oil), which has been implicated in immediate pseudoallergic reactions. Although CARPA has been widely discussed in oncology, immunology, and nanomedicine, its relevance to a broader range of infusion and injectable therapies remains underrecognized. This narrative review summarizes the mechanisms, clinical features, drug classes, and formulation-related risk factors associated with complement activation and complement-associated reactions, with particular attention to injectables and compounded therapies. Greater awareness of complement-activating formulations may help recognize pseudoallergic reactions, evaluate excipients more carefully, and improve the safe administration of infusion and injectable therapies.
Mas-related G protein-coupled receptor X2 (MRGPRX2) is a mast-cell-enriched receptor that mediates immunoglobulin E-independent activation by structurally diverse neuropeptides, host-defense peptides, microbial products, and selected cationic drugs. Its biology links tissue stress and neuroimmune signaling to degranulation, vascular responses, pruritus, barrier dysfunction, and inflammatory amplification, but the extent to which individual diseases depend on this pathway remains uncertain. The strongest clinical rationale begins with non-IgE-mediated immediate drug hypersensitivity, for which MRGPRX2 provides a direct mechanistic framework, although rocuronium illustrates the need to distinguish human MRGPRX2 pharmacology from murine Mrgprb2 and from IgE-mediated perioperative allergy. In atopic dermatitis, preclinical and human skin data support a potential amplifier role in type 2 inflammation and itch, but a randomized phase 2b study of EVO756 did not demonstrate efficacy in an unselected population. In chronic urticaria, challenge, biomarker, and genetic studies suggest an MRGPRX2-responsive subgroup within a heterogeneous disease, whereas a randomized phase 2b study of EVO756 in unselected chronic spontaneous urticaria was also negative despite earlier pharmacodynamic activity. Ulcerative colitis provides additional human tissue evidence for an MRGPRX2-associated mast-cell circuit, although murine Mrgprb2 studies show context-dependent protective and pathogenic effects. Emerging evidence in chronic prurigo, allergic contact dermatitis, asthma, mastocytosis, rheumatoid arthritis, synovial inflammation, and neurogenic inflammation is also considered, with explicit separation of human observations from mouse-model evidence. We integrate these findings with receptor pharmacology and early clinical development, emphasizing evidence hierarchy, validated biomarker needs, patient selection, tissue target engagement, safety, and trial design. Current data support MRGPRX2 as an investigational endotype-defining pathway rather than a universal driver of allergic or immune-mediated disease.